Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: May 30, 2023

Details for Patent: 9,657,003

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 9,657,003 protect, and when does it expire?

Patent 9,657,003 protects NUBEQA and is included in one NDA.

This patent has ninety-three patent family members in thirty-six countries.

Summary for Patent: 9,657,003

Title:	Androgen receptor modulating compounds
Abstract:	The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
Inventor(s):	Wohlfahrt; Gerd (Helsinki, FI), Tormakangas; Olli (Turku, FI), Salo; Harri (Turku, FI), Hoglund; Iisa (Turku, FI), Karjalainen; Arja (Espoo, FI), Koivikko; Pia (Littoinen, FI), Holm; Patrik (Lielahti TL, FI), Rasku; Sirpa (Vantaa, FI), Vesalainen; Anniina (Paimio, FI)
Assignee:	ORION CORPORATION (FI)
Application Number:	14/598,973
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 9,657,003

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Healthcare	NUBEQA	darolutamide	TABLET;ORAL	212099-001	Jul 30, 2019		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y	Y		TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,657,003

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	078793	⤷ Try a Trial
Australia	2007213960	⤷ Try a Trial
Australia	2010311299	⤷ Try a Trial
Brazil	112012008823	⤷ Try a Trial
Brazil	PI0708035	⤷ Try a Trial
Brazil	PI0708036	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson

AstraZeneca

Express Scripts

Mallinckrodt

Moodys

McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.